Background. Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSIs) are associated with significant mortality. Daptomycin exhibits concentration-dependent activity vs VRE in vitro, yet the clinical impact of higher-dose strategies remains unclear.
daptomycin PD in the treatment of serious VRE infections [16] . Previous in vitro analyses comparing daptomycin (6, 8, 10 , 12 mg/kg/day) vs VRE isolates in a high-inoculum pharmacokinetic (PK)/PD model demonstrated that bactericidal activity was not sustained at 6 or 8 mg/kg/day and doses of at least 10 mg/kg/day were required. Additionally, prevention of the emergence of daptomycin-nonsusceptible (DNS) Enterococcus faecium mutants was only achievable at ≥12 mg/kg/day [16] .
The definition of "high-dose" daptomycin varies in the literature, but is most commonly ≥8 mg/kg or ≥10 mg/kg [18] [19] [20] [21] [22] [23] . These daptomycin dosing strategies been shown to be relatively safe and effective; however, there is a paucity of comparative data in VRE-BSI [18] [19] [20] [21] [22] [23] . Although infectious diseases (ID) specialist consultation has consistently been shown to improve mortality in patients with other gram-positive BSIs, this effect in VRE-BSI has not been extensively evaluated [24] [25] [26] . We sought to compare clinical and safety outcomes of various intensities of daptomycin dosing strategies and determine the impact of ID consultation on clinical outcomes in the management of VRE-BSI.
METHODS

Study Design, Population, and Treatment Groups
We conducted a retrospective cohort study of hospitalized patients admitted between 2004 and 2014 to any Veterans Affairs medical center (VAMC). Other inclusion criteria were (1) age ≥18 years; (2) ≥1 blood culture positive for VRE (E. faecium or Enterococcus faecalis); and (3) treatment with daptomycin. Exclusion criteria were (1) daptomycin treatment <48 hours; (2) daptomycin dose <5.5 mg/kg/day; (3) hemodialysis; (4) daptomycin dosing interval >24 hours; (5) initial corresponding DNS isolate; and (6) previous or concurrent treatment with another active anti-VRE agent during the index VRE-BSI episode. If a patient experienced multiple VRE-BSIs during the study period, only the first case was analyzed. We cannot exclude for the possibility that subjects were previously included in other analyses of daptomycin effectiveness for VRE-BSI within the VA healthcare system; however, due to substantially different inclusion and exclusion criteria, we expect the level of overlap to be small [10] .
Patients were classified into 3 comparison groups based on daptomycin dose. Daptomycin doses of 6 (±0.5) mg/kg/day were classified as standard-dose, 8 (±0.5) mg/kg/day as medium-dose, and ≥10 mg/kg/day as high-dose. All doses were categorized according to total body weight and patients treated outside designated standard, medium, and high weight-based dosing parameters were not included in the primary analysis. However, an additional post hoc sensitivity analysis was performed to analyze the comparative effectiveness of daptomycin dosing strategies in the overall cohort, including those treated outside prespecified weight-based parameters. This study was approved by the Kansas City VAMC institutional review board and granted a waiver of informed consent.
Data Sources and Collection
Cases of VRE-BSI meeting study criteria were identified through query of clinical and administrative databases. Data extracted included admission records, patient demographics, vital signs, laboratory data, microbiological data, antimicrobial treatment data, statin use, comorbidities, ID consultation (within 48 hours of index blood culture), and vital status. Retrospective review of the electronic medical record was conducted on all patients to determine the source of VRE-BSI as documented by a treating physician and to confirm cases of infective endocarditis according to modified Duke criteria [27] . All antimicrobial susceptibilities were determined during routine clinical care according to institution-specific procedures.
Outcomes
The primary outcome was overall survival, defined from the time of index VRE-positive blood culture. Secondary outcomes included 30-day all-cause mortality (death within 30 days of index VRE-positive blood culture), time to microbiological clearance (time from initiation of daptomycin treatment until first negative culture), 60-day VRE-BSI recurrence (defined from the end of daptomycin treatment and excluding those who died during this period), and median hospital length of stay (time from index VRE-positive blood culture until discharge, excluding those who died during hospitalization). We also assessed development of treatment-emergent DNS and 60-day VRE recurrence with a DNS isolate from any source.
Safety Analysis
Patients were evaluated during treatment for creatine phosphokinase (CPK) elevation. Elevated CPK was first evaluated as a dichotomous variable, adapted from previous criteria [28] [29] [30] . Among patients with a normal baseline CPK level, CPK elevation was defined as a follow-up CPK level ≥3 times the upper limit of normal (ULN; based on individual hospital references ranges) for up to 3 days after daptomycin discontinuation. Among patients with an elevated baseline CPK level, CPK elevation was defined as a follow-up CPK level ≥5 times the ULN for up to 3 days after daptomycin discontinuation. Creatine phosphokinase levels were then evaluated as a continuous variable, with values normalized to a standard reference range, defined as the most commonly utilized reference range among hospitals contributing cases, according to previously described methods [31] . A sensitivity analysis was performed in which CPK elevation was defined as a level ≥3 times the ULN at any time while on daptomycin. Finally, we evaluated the association between CPK elevation and acute kidney injury per RIFLE (risk, injury, failure, loss of kidney function, and end-stage kidney disease) criteria [32] .
Statistical Analysis
For univariable analyses, categorical data were compared by χ 2 test and continuous data by Kruskal-Wallis test. Overall survival and time to microbiological clearance were compared between groups using the Kaplan-Meier method and log-rank test for trend. Overall survival was also compared by Cox regression. Daptomycin treatment group was forced into the Cox proportional hazards model and all other variables associated with daptomycin treatment group or survival (P < .2) were entered in a forward stepwise manner. Only variables that significantly confounded the relationship between daptomycin treatment group and survival, resulting in a ≥10% change in the associated hazard ratio (HR), were retained in the final parsimonious model. Secondary analyses were conducted in subgroups of obesity (body mass index ≥30 kg/m 2 ), intensive care unit admission, ID consultation, and causative VRE species. The effects of daptomycin treatment group on 30-day mortality after stratification by concomitant aminoglycoside therapy and concomitant β-lactam therapy were evaluated using the MantelHaenszel procedure and Breslow-Day test of homogeneity. For comparisons of 3 groups, a Bonferroni-adjusted P < .017 was deemed statistically significant. The significance level was .2 for the Breslow-Day test and .05 for all other tests. Statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, North Carolina).
RESULTS
Of the 1293 daptomycin-treated patients with VRE-BSI, 383 (29.6%) were excluded due to dosing outside the prespecified parameters, resulting in a cohort of 911 patients included in the primary analysis. Of these patients, 709 (77.8%) were treated with standard-dose, 142 (15.6%) with medium-dose, and 60 (6.6%) with high-dose daptomycin. A total of 81 VAMCs contributed cases across 36 United States and the District of Columbia. The median dose in the standard-dose group was 6.02 mg/kg (interquartile range [IQR], 5.70-6.38 mg/kg), 7.90 mg/kg (IQR, 7.60-8.22 mg/kg) in the medium-dose group, and 10.2 mg/kg (IQR, 9.76-11.0 mg/kg) in the high-dose group.
Patient characteristics were compared and many significant differences were observed (Table 1) . Quantitative daptomycin MIC data for index VRE blood isolates were reported for 43 of 911 cases (4.7%). All isolates were daptomycin susceptible ( Table 2 ; MIC 50 (50th percentile MIC), 4 μg/mL; MIC 90 (90th percentile MIC), 4 μg/mL; range, 0.25-4 μg/mL).
Overall survival differed significantly between daptomycin treatment groups ( Figure 1 ; log-rank test, P = .006). There was no difference in survival between standard-and medium-dose daptomycin-treated patients (HR, 1.02; 95% confidence interval [CI], 0.71-1.39; P = .908). However, when compared to high-dose daptomycin, both standard-dose (HR, 2.68; 95% CI, 1.33-3.06; P = .002) and medium-dose daptomycin treatment (HR, 2.66; 95% CI, 1.33-3.92; P = .003) were associated with significantly poorer survival. After adjusting for confounding factors (Table 3) , high-dose daptomycin remained associated with improved survival compared with standard-dose (adjusted HR [aHR], 2.58; 95% CI, 1.27-4.88; P = .004) and medium-dose daptomycin (aHR, 2.52; 95% CI, 1.27-5.00; P = .008). Infectious diseases consultation was also independently associated with improved survival (aHR, 0.58; 95% CI, .46-.75; P < .001).
Microbiological clearance rates differed significantly between groups ( Figure 2 ; log-rank test, P < .001). Compared with standard-dose daptomycin, both medium-dose (HR, 0.78; 95% CI, .55-.90; P = .012) and high-dose daptomycin (HR, 0.70; 95% CI, .41-.84; P = .006) were associated with significantly improved microbiological clearance. However, no difference in microbiological clearance was observed between medium-and high-dose daptomycin treatment (HR, 0.89; 95% CI, .60-1.22; P = .459). High-dose daptomycin was also associated with a reduction in the risk of 30-day mortality (risk ratio, 0.83; 95% CI, .74-.94; P = .015). There were no statistically significant differences between the 3 treatment groups for any other secondary outcome (Table 4) . A single case of treatment-emergent DNS VRE-BSI was observed, occurring in the standard-dose group. One case of recurrent DNS VRE urinary tract infection was observed after recent daptomycin discontinuation in a standard-dosed patient.
Safety Analysis
Creatine phosphokinase elevation occurred in 7 of 595 (1.2%) patients with serial CPK measurements. In the standard-dose daptomycin group, 6 of 441 (1.4%) experienced elevated CPK, compared with 1 of 103 (1.0%) in the medium-dose group and 0 of 51 in the high-dose group. There was no association between CPK elevation and acute kidney injury (no CPK elevation, n = 326/571 [57.1%] vs CPK elevation, n = 4/7 [57.1%]; P > .999). Overall, no difference in the risk of CPK elevation was observed between the 3 treatment groups (P = .504). 
Subgroup and Sensitivity Analyses
The relationship between improved survival with high-dose daptomycin in comparison to standard-and medium-dose daptomycin persisted in secondary subgroup analyses (Figure 3 ). Table 1 ). Nonetheless, the relationship between high-dose daptomycin and lower mortality persisted after controlling for effect modification by these agents in the pooled analysis (Supplementary Table 1 ). In the overall cohort of daptomycin-treated patients (n = 1293), higher daptomycin doses (mg/kg) were associated with improved survival (HR, 0.82; 95% CI, .76-.88; P < .001).
DISCUSSION
We compared the clinical effectiveness and safety of various daptomycin dosing strategies for VRE-BSI. The principal finding was that high-dose daptomycin treatment was associated with improved survival compared with standard-and medium-dose daptomycin, without an apparent increase in the risk of CPK elevation. The relationship between high-dose daptomycin and improved survival relative to lower dosing strategies persisted after accounting for confounding factors and in subgroups of interest. While high-dose daptomycin had previously demonstrated improved VRE killing in vitro, the present study is the first to demonstrate a clear clinical benefit of this strategy, to our knowledge [16] .
Overall mortality in the present study was high, consistent with previous VRE-BSI studies [6, 9, 10, 33] . Thirty-day mortality was similar in both standard-and medium-dose groups (approximately 30%), while the risk of mortality was halved among high-dose daptomycin-treated patients. Many clinicians have implemented an 8 mg/kg daptomycin dosing strategy to increase the probability of PD target attainment while minimizing potential toxicity. In the present study, medium-dose daptomycin was associated with improved microbiological clearance relative to standard-dose daptomycin, which would appear to support this strategy. Previous research has demonstrated that shorter time to microbiological clearance is associated with lower mortality in enterococcal BSI [34, 35] . However, only high-dose daptomycin treatment was associated with an improvement in survival. The reason for this mortality benefit More patients in the high-dose group received concomitant aminoglycoside and β-lactam therapy, which could have resulted in synergistic effects [36] . However, high-dose daptomycin remained significantly associated with lower mortality after accounting for effect modification. Of the potential agents analyzed, gentamicin, ampicillin with or without sulbactam, and piperacillin-tazobactam appeared to be most effective as combination therapy [36] . Unfortunately, some other potentially synergistic agents, such as ceftaroline, were not utilized enough to adequately power a stratified analysis [37] .
Few studies have explored the effect of daptomycin dose on clinical outcomes in VRE-BSI [18, 19, [21] [22] [23] . Gallagher et al observed improved clinical success associated with daptomycin ≥6 mg/kg compared to lower doses [38] . Recently published data also indicated a benefit in 14-day mortality with high-dose daptomycin (>9 mg/kg) vs lower-dose daptomycin (6-9 mg/kg) in a small cohort of daptomycin-treated VRE-BSI patients in Taiwan [33] . However, this study did not compare standard-, medium-, and high-dose daptomycin strategies; therefore, it was unclear if the poorer outcomes were driven by patients receiving standard doses. Additionally, a recent large-scale postmarketing analysis demonstrated numerically higher rates of treatment success in enterococcal infections with higher daptomycin doses [22] . Despite this promising data, a robust patient-level comparison of clinical and safety outcomes between 6, 8, and ≥10 mg/kg daptomycin dosing strategies had not been performed prior to the present study.
Simulations of clinical trial data suggest that high-dose daptomycin may increase the risk of skeletal muscle toxicity [30] . However, "real world" observational studies have not demonstrated appreciable increases in the risk of elevated CPK with higher daptomycin doses [10, 18, 19, [21] [22] [23] 33] . In a large safety analysis (n = 5989), no significant differences in overall adverse events were observed between daptomycin ≤6 mg/kg vs ≥8 mg/ kg, although CPK elevations were numerically more common with higher doses (1.0% vs 2.8%) [22] . Consistent with the body of evidence from previous studies, we did not observe increased CPK elevation with higher daptomycin doses. Notably, this risk may have been underestimated in the present study due to the exclusion of patients with severely impaired renal function or requiring hemodialysis. Due to the rarity of elevated CPK events observed, we were left underpowered to detect differences between the 3 daptomycin treatment groups and associations with statin use. Cases right-censored at the end of treatment.
Abbreviations: BSI, bloodstream infection; CI, confidence interval. a Standard-dose (6 mg/kg; n = 709), medium-dose (8 mg/kg; n = 142), high-dose (≥10 mg/kg; n = 60).
b Within 48 h of beginning treatment. The optimal dosing weight for daptomycin in obesity remains unclear. Limited PK data suggest a moderate increase in daptomycin AUC in this population, although the FDAapproved product labeling does not endorse alternative weight-based dosing in obesity [14, [41] [42] [43] . To reduce cost and the risk of adverse events, some institutions have adopted daptomycin dosing utilizing ideal or adjusted body weights rather than the recommended weight-based dosing [30, 43, 44] . However, studies evaluating these strategies have featured a limited number of patients with VRE infection and have been underpowered [43, 44] . In consideration of our observation that high-dose daptomycin conferred a significant survival benefit even among obese patients, we would recommend dosing of daptomycin using total body weight in VRE-BSI until more robust clinical data supporting alternative weight-based dosing strategies are available. Suboptimal dosing of daptomycin is of particular concern in cases of VRE-BSI with elevated daptomycin MIC and may increase the risk for treatment-emergent DNS [15, 16] .
While the benefit of ID consultation has been demonstrated for a number of other serious infections, the impact in VRE-BSI had yet to be extensively evaluated prior to the present study [24] [25] [26] . Although ID specialists appeared to be more likely to recommend high-dose daptomycin, the relationship persisted after adjusting for daptomycin dose and other confounding factors. The reason for this observed benefit warrants further research, but may be related to more aggressive investigation and control of the nidus of infection among ID providers. Our data suggest that ID consultation is of benefit in the management of these vexing infections and thus should be routinely brought to bear in their treatment.
The present study should be interpreted within the context of its limitations and the population studied. This was a retrospective observational study and suffers from the limitations of such a design, including an inability to control for the timing and frequency of follow-up blood cultures and documentation of source control. The VA patient population is primarily male, of advanced age, and with a high comorbidity a Analysis excludes those with in-hospital mortality; includes standard-dose (n = 499), medium-dose (n = 99), high-dose (n = 48).
b Analysis excludes those with 60-day mortality; includes standard-dose (n = 416), medium-dose (n = 77), high-dose (n = 42).
c From any source; analysis excludes those with 60-day mortality; includes standard-dose (n = 416), medium-dose (n = 77), high-dose (n = 42). burden. These results should ideally be replicated in populations poorly represented in the present study, including solid organ and hematopoietic stem cell transplant recipients. Quantitative daptomycin MIC data were available in a limited number of patients, although the distributions were relatively similar among evaluable cases. There is increasing evidence demonstrating the clinical importance of daptomycin MIC in VRE infection and this may have represented an undermeasured confounder in the present study [15] . However, because these data would not have been available to clinicians at the time of treatment initiation, it is highly unlikely to have affected treatment decisions and therefore should not substantively differ between groups. Due to limited sample size and low event rates, we were underpowered to compare some secondary outcomes, including recurrent and treatment-emergent DNS infections. In summary, we report improved survival associated with high-dose daptomycin treatment for VRE-BSI vs medium-and standard-dose approaches, without an apparent increase in elevated CPK events. Consultation with ID was independently associated with improved survival. Based on these results, we believe that high-dose daptomycin (≥10 mg/kg total body weight) should be considered over lower dosing strategies for the treatment of VRE-BSI.
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